Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 17,399 shares, a decrease of 84.8% from the June 30th total of 114,234 shares. Based on an average daily trading volume, of 41,300 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after acquiring an additional 10,308 shares during the last quarter. Sei Investments Co. boosted its stake in Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares during the period. Smartleaf Asset Management LLC grew its position in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the last quarter. IFP Advisors Inc grew its position in Global X Genomics & Biotechnology ETF by 20.8% in the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after purchasing an additional 489 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $575,000. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Down 1.8%

Shares of NASDAQ:GNOM traded down $0.98 on Friday, reaching $53.92. 13,696 shares of the company’s stock were exchanged, compared to its average volume of 15,486. The business’s 50-day moving average is $52.16 and its two-hundred day moving average is $48.19. Global X Genomics & Biotechnology ETF has a fifty-two week low of $34.04 and a fifty-two week high of $59.48. The firm has a market capitalization of $78.72 million, a price-to-earnings ratio of -23.04 and a beta of 1.16.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently declared a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were issued a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is -27.35%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.